Bioactivity | HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 inhibits EGFR 19 del, EGFR L858R, EGFR wild type and EGFR T790M with IC50s of 1.3, 1.5, 4.0 and 977 nM, respectively. HX103 can be used for quantifying active-EGFR to predict agent sensitivity in NSCLC patients with EGFR-activating mutations[1]. |
Invitro | 与 PBS 或 H2O 水溶液相比,HX103 在乙腈中具有显著的荧光增强作用,并具有环境敏感性质[1]。HX103 (5 μM) 在 PBS 中不发荧光,但在加入野生型或突变型 EGFR (L858R 和 19del) 后显示出高荧光。HX103 对 EGFR 野生型和主要突变体 (L858R和19del) 具有选择性,但对获得性耐药突变 EGFR T790M 较不敏感[1]。与 EGFR 野生型 (Kd = 2.7 ± 0.4 µM)和获得性耐药突变型 T790M (Kd = 6.6 ± 4.6µM) 相比,HX103 对 EGFR L858R (Kd = 0.8 ± 0.3 µM) 和 EGFR 19del (Kd = 1.1 ± 0.2 µM) 具有稍强的结合亲和力[1]。HX103 (0.3-10 μM; 2 h) 靶向 EGFR-酪氨酸激酶的活性位点,通过与 ATP 竞争抑制 EGFR的激活[1]。 Western Blot Analysis[1] Cell Line: |
Name | HX103 |
CAS | 2566466-98-4 |
Formula | C26H25ClFN7O5S |
Molar Mass | 602.04 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Deng H, et al. A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. Nat Commun. 2022 Nov 14;13(1):6944. |